Sanofi's Pruning Shears: A Necessary Cut or a Sign of Failing Ambition?
The decision by Sanofi to abandon its clinical development of amlitelimab, an eczema treatment candidate, has sent shockwaves through the pharmaceutical industry.
On the surface, it appears to be another example of a Big Pharma giant culling its R&D pipeline.